| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2018 | MRK Merck & Co., Inc. | Deluca Richard R.45 | EVP&Pres, Merck Animal Health | Sell | 25,467 | $72.00 | $1,833,738.60 | -31.0% | |
| Oct 29, 2018 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 5,500 | $107.13 | $589,237.00 | -12.7% | |
| Oct 26, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $5.28 | $972,072.00 | -0.5% | |
| Oct 24, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 250,000 | $5.35 | $1,337,500.00 | -7.8% | |
| Oct 22, 2018 | AZN Astrazeneca Plc | Astrazeneca Plc | 10% Owner | Buy | 600,000 | $5.00 | $3,000,000.00 | +25.0% | |
| Oct 19, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 100 | $7.50 | $750.00 | -1.0% | |
| Oct 19, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,150 | $7.45 | $23,467.50 | -2.2% | |
| Oct 19, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $5.56 | $1,016,368.00 | -1.4% | |
| Oct 18, 2018 | ESPR Esperion Therapeutics, Inc. | Newton Roger S | Director | Sell | 22,173 | $50.02 | $1,108,997.46 | -1.3% | |
| Oct 17, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 174,696 | $113.25 | $19,783,623.22 | -0.1% | |
| Oct 17, 2018 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 314 | $61.50 | $19,311.00 | -1.1% | |
| Oct 16, 2018 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 22,996 | $61.06 | $1,404,025.96 | -13.5% | |
| Oct 16, 2018 | BHC Bausch Health Companies Inc. | Ackermann Christina | EVP And General Counsel | Sell | 19,946 | $24.98 | $498,302.32 | -15.7% | |
| Oct 15, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $16.53 | $413,250.00 | -6.5% | |
| Oct 15, 2018 | TLPH Talphera, Inc. | Hamel Lawrence G | Chief Development Officer | Sell | 5,216 | $5.00 | $26,080.00 | -14.9% | |
| Oct 15, 2018 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $3.00 | $30,000.00 | -1.1% | |
| Oct 15, 2018 | TLPH Talphera, Inc. | Dasu Badri N | Chief Engineering Officer | Sell | 28,351 | $5.00 | $141,755.00 | -34.4% | |
| Oct 15, 2018 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnotes 1 And 2 | Buy | 5,541,562 | $0.00 | - | New | |
| Oct 12, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $5.55 | $1,020,832.00 | -0.5% | |
| Oct 10, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 250,000 | $5.85 | $1,462,750.00 | -7.8% | |
| Oct 9, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 10,672 | $115.91 | $1,237,012.86 | - | |
| Oct 8, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 14,632 | $115.91 | $1,696,039.02 | - | |
| Oct 5, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $5.91 | $1,080,348.00 | -1.4% | |
| Oct 5, 2018 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 233,301 | $17.81 | $4,155,570.17 | -67.5% | |
| Oct 4, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 116,038 | $112.67 | $13,073,950.24 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.